BREAST CANCER

Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab.

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.

Adam M. Brufsky, MD, PhD, gives a summary of his talk at the 13th Annual International Congress on the Future of Breast Cancer®. Brufsky discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses ESR1 mutations in primary breast cancer.

Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.

Graham Colditz, MD, DrPH, associate director, Prevention and Control, Alvin J. Siteman Cancer Center, discusses the need to focus on breast cancer prevention in low and middle income countries.

Triple-negative breast cancer (TNBC) accounts for only 15% to 20% of breast cancers in the US.

The FDA has approved gadobutrol (Gadavist) injection for intravenous use with breast MRI to detect and identify the extent of disease.

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

Halle Moore, MD, discusses a phase III trial that looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.

Adam M. Brufsky, MD, PhD, discusses the results of a study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or MBC.

Abemaciclib demonstrated unexpected single-agent activity in patients with hormone receptor (HR)-positive metastatic breast cancer and a clinical benefit rate exceeding 70% in combination with fulvestrant.

A joint analysis of two phase III trials involving a total of 4690 premenopausal women with HR+ breast cancer demonstrated that adjuvant use of exemestane reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen.

Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.

A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in disease-free survival (DFS) over the standard therapy with trastuzumab alone.

Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.

The dosing frequency of zoledronic acid (Zometa) can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.

The ASCO clinical practice guideline now recommends treatment with adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses the advantages and limitations of nipple-sparing mastectomy.

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease, according to findings from a large, retrospective study involving 80,000 patients.

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.

Grant W. Carlson, MD, from Emory University Hospital, discusses some pros and cons associated with contralateral prophylactic mastectomy.